Epiphany's valomaciclovir meets Phase IIb endpoint

Epiphany Biosciences Inc. (San Francisco, Calif.) said the two highest doses (2 and 3 g) of once-daily valomaciclovir ( EPB-348) met the primary endpoint of non-inferiority to three times daily Valtrex valacyclovir in time to complete crusting of shingles rash in a Phase IIb trial to treat varicella zoster virus infection. The lowest dose (1 g) of valomaciclovir missed the primary endpoint. The highest dose was superior to valacyclovir in time to complete crusting of shingles rash (p<0.007). ...